94 research outputs found

    The Next Generation Virgo Cluster Survey XVI. The Angular Momentum of Dwarf Early-Type Galaxies from Globular Cluster Satellites

    Full text link
    We analyze the kinematics of six Virgo cluster dwarf early-type galaxies (dEs) from their globular cluster (GC) systems. We present new Keck/DEIMOS spectroscopy for three of them and reanalyze the data found in the literature for the remaining three. We use two independent methods to estimate the rotation amplitude (Vmax) and velocity dispersion (sigma_GC) of the GC systems and evaluate their statistical significance by simulating non-rotating GC systems with the same number of GC satellites and velocity uncertainties. Our measured kinematics agree with the published values for the three galaxies from the literature and, in all cases, some rotation is measured. However, our simulations show that the null hypothesis of being non-rotating GC systems cannot be ruled out. In the case of VCC1861, the measured Vmax and the simulations indicate that it is not rotating. In the case of VCC1528, the null hypothesis can be marginally ruled out, thus, it might be rotating although further confirmation is needed. In our analysis, we find that, in general, the measured Vmax tends to be overestimated and the measured sigma_GC tends to be underestimated by amounts that depend on the intrinsic Vmax/sigma_GC, the number of observed GCs (N_GC), and the velocity uncertainties. The bias is negligible when N_GC>~20. In those cases where a large N_GC is not available, it is imperative to obtain data with small velocity uncertainties. For instance, errors of <2km/s lead to Vmax<10km/s for a system that is intrinsically not rotating.Comment: ApJ in press. 20 pages, 17 figures, 5 table

    The Most Massive Ultra-Compact Dwarf Galaxy in the Virgo Cluster

    Full text link
    We report on the properties of the most massive ultra-compact dwarf galaxy (UCD) in the nearby Virgo Cluster of galaxies using imaging from the Next Generation Virgo Cluster Survey (NGVS) and spectroscopy from Keck/DEIMOS. This object (M59-UCD3) appears to be associated with the massive Virgo galaxy M59 (NGC 4621), has an integrated velocity dispersion of 78 km/s, a dynamical mass of 3.7×108M3.7\times10^8 M_\odot, and an effective radius (ReR_e) of 25 pc. With an effective surface mass density of 9.4×1010M/kpc29.4\times10^{10} M_\odot/kpc^2, it is the densest galaxy in the local Universe discovered to date, surpassing the density of the luminous Virgo UCD, M60-UCD1. M59-UCD3 has a total luminosity of Mg=14.2M_{g'}=-14.2 mag, and a spectral energy distribution consistent with an old (14 Gyr) stellar population with [Fe/H]=0.0 and [α\alpha/Fe]=+0.2. We also examine deep imaging around M59 and find a broad low surface brightness stream pointing towards M59-UCD3, which may represent a tidal remnant of the UCD progenitor. This UCD, along with similar objects like M60-UCD1 and M59cO, likely represents an extreme population of tidally stripped galaxies more akin to larger and more massive compact early-type galaxies than to nuclear star clusters in present-day dwarf galaxies.Comment: 6 pages, 4 figures, 1 table, accepted for publication in ApJ Letter

    Phytoremediatory efficiency of Chrysopogon zizanioides in the treatment of landfill leachate: a case study

    Get PDF
    A common approach for waste management is their disposal in landfills, which is usually associated with the production of dangerous gases and of liquid leachate. Due to its toxicity, polluted liquid negatively impacts on the environment with the possible contamination of large volumes of soil, groundwater, and surface water. Leachate remediation is therefore subject of intensive research, and phytoremediation has been achieving increasing interest in recent decades.We describe here the suitability of vetiver grass for the remediation of two leachates collected in urban landfills of northern Italy, characterized by different composition. Our objective was measuring the accumulation/tolerance potential of this species and the evapotranspiration ability in a pot experiment, to evaluate applicability of vetiver plants for the reduction and decontamination of landfill leachate. Plants were grown for 4 months in pots with a zeolite growth bed and watered with either tap water (control) or undiluted landfill leachate. Plant growth and fitness and elemental content in shoots and roots were evaluated at the end of the experiment. In these experimental conditions, the high bioaccumulation of metals highlights the suitability of this species for its employment in phytoremediation; however, vetiver growth under leachate treatment was strongly dependent on leachate composition, making a case-to-case evaluation of plant tolerance necessary before large-scale application

    New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series

    Get PDF
    Background Myasthenia gravis (MG) is an autoimmune disease that targets acetylcholine receptor (AChR) of the neuromuscular junction. New-onset MG after SARS-CoV-2 vaccination has rarely been reported. Case presentation We report about three patients who presented new-onset myasthenia gravis after receiving mRNA SARSCoV-2 vaccination. The patients were all males and older than 55 years. All the patients presented with ocular and bulbar symptoms. The interval between vaccine administration and MG onset ranged from 3 days after the frst dose to 10 days after the second dose. All the patients had elevated serum AChR antibodies and responded to pyridostigmine. Two out of three patients were successfully treated with IVIG or plasma exchange and with long-term immunosuppression. Conclusions MG is a rare disease; clinicians should be aware of possible new-onset MG after SARS-CoV-2 vaccination, especially with the current recommendation of booster doses. The hyperstimulation of the innate immune system or the exacerbation of a subclinical pre-existing MG could be possible explanations

    COVID-19-associated Guillain-Barré syndrome in the early pandemic experience in Lombardia (Italy)

    Get PDF
    Objective To estimate the incidence and describe clinical characteristics and outcome of GBS in COVID-19 patients (COVID19-GBS) in one of the most hit regions during the frst pandemic wave, Lombardia. Methods Adult patients admitted to 20 Neurological Units between 1/3–30/4/2020 with COVID19-GBS were included as part of a multi-center study organized by the Italian society of Hospital Neuroscience (SNO). Results Thirty-eight COVID19-GBS patients had a mean age of 60.7 years and male frequency of 86.8%. CSF albuminocytological dissociation was detected in 71.4%, and PCR for SARS-CoV-2 was negative in 19 tested patients. Based on neurophysiology, 81.8% of patients had a diagnosis of AIDP, 12.1% of AMSAN, and 6.1% of AMAN. The course was favorable in 76.3% of patients, stable in 10.5%, while 13.2% worsened, of which 3 died. The estimated occurrence rate in Lombardia ranges from 0.5 to 0.05 GBS cases per 1000 COVID-19 infections depending on whether you consider positive cases or estimated seropositive cases. When we compared GBS cases with the pre-pandemic period, we found a reduction of cases from 165 to 135 cases in the 2-month study period in Lombardia. Conclusions We detected an increased incidence of GBS in COVID-19 patients which can refect a higher risk of GBS in COVID-19 patients and a reduction of GBS events during the pandemic period possibly due to a lower spread of more common respiratory infectious diseases determined by an increased use of preventive measures

    Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production

    Get PDF
    BACKGROUND: As critical mediators of local and systemic inflammatory responses, cytokines are produced in the brain following ischaemic stroke. Some have been detected in the circulation of stroke patients, but their role and source is unclear. Focusing primarily on interleukin(IL)-1-related mechanisms, we serially measured plasma inflammatory markers, and the production of cytokines by whole blood, from 36 patients recruited within 12 h and followed up to 1 year after acute ischaemic stroke (AIS). RESULTS: Admission plasma IL-1 receptor antagonist (IL-1ra) concentration was elevated, relative to age-, sex-, and atherosclerosis-matched controls. IL-1β, soluble IL-1 receptor type II, tumour necrosis factor (TNF)-α, TNF-RII, IL-10 and leptin concentrations did not significantly differ from controls, but peak soluble TNF receptor type I (sTNF-RI) in the first week correlated strongly with computed tomography infarct volume at 5–7 days, mRS and BI at 3 and 12 months. Neopterin was raised in patients at 5–7 d, relative to controls, and in subjects with significant atherosclerosis. Spontaneous IL-1β, TNF-α and IL-6 gene and protein expression by blood cells was minimal, and induction of these cytokines by lipopolysaccharide (LPS) was significantly lower in patients than in controls during the first week. Minimum LPS-induced cytokine production correlated strongly with mRS and BI, and also with plasma cortisol. CONCLUSION: Absence of spontaneous whole blood gene activation or cytokine production suggests that peripheral blood cells are not the source of cytokines measured in plasma after AIS. Increased plasma IL-1ra within 12 h of AIS onset, the relationship between sTNF-RI and stroke severity, and suppressed cytokine induction suggests early activation of endogenous immunosuppressive mechanisms after AIS

    Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome

    Get PDF
    BACKGROUND: Cerebral ischaemia initiates an inflammatory response in the brain and periphery. We assessed the relationship between peak values of plasma interleukin-6 (IL-6) in the first week after ischaemic stroke, with measures of stroke severity and outcome. METHODS: Thirty-seven patients with ischaemic stroke were prospectively recruited. Plasma IL-6, and other markers of peripheral inflammation, were measured at pre-determined timepoints in the first week after stroke onset. Primary analyses were the association between peak plasma IL-6 concentration with both modified Rankin score (mRS) at 3 months and computed tomography (CT) brain infarct volume. RESULTS: Peak plasma IL-6 concentration correlated significantly (p < 0.001) with CT brain infarct volume (r = 0.75) and mRS at 3 months (r = 0.72). It correlated similarly with clinical outcome at 12 months or stroke severity. Strong associations were also noted between either peak plasma C-reactive protein (CRP) concentration or white blood cell (WBC) count, and all outcome measures. CONCLUSIONS: These data provide evidence that the magnitude of the peripheral inflammatory response is related to the severity of acute ischaemic stroke, and clinical outcome

    Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

    Get PDF
    Funder: Funder: Fundación bancaria ‘La Caixa’ Number: LCF/PR/PR16/51110003 Funder: Grifols SA Number: LCF/PR/PR16/51110003 Funder: European Union/EFPIA Innovative Medicines Initiative Joint Number: 115975 Funder: JPco-fuND FP-829-029 Number: 733051061Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease
    corecore